Oxaliplatin: an effective treatment in colorectal cancer

Abstract

Colorectal cancer is one of the most common malignancies around the world. Oxaliplatin is a new platinum compound
with promising activity in colorectal cancer treatment. Based on the analysis of preclinical data. Because Oxaliplatin
can lead to ICD (Immunogenic cell death), the study aims to figure out whether increasing concentrations and treatment
durations with Oxaliplatin can kill colorectal cancer cells to test whether Oxaliplatin has a significant effect on colorectal
cancer treatment. Using the human colorectal cancer cell line HCT116, the cancer cells will be treated with Oxaliplatin
and PBS (negative control) at concentrations 1 mM, 10 mM, or 100 mM in a dose-dependent and duration-dependent
manner (1,3,6,12,24 hours ). Measure killing in vitro with MTT assay and measure tumor size in vivo. Also, measure
HMGB-1 released by western blot and CRT by FACS. The positive control is cisplatin, and the negative is PBS/DMSO
for in vitro and saline solution for in vivo. The study’s findings will supply insight into the latent capacity of Oxaliplatin
as a treatment for colorectal cancer in the future.